Prof Hisham Mehanna speaks with ecancer at ESMO 2018 in Munich about results from a trial comparing cetuximab and cisplatin for patients with HPV-related oropharyngeal cancer receiving radical radiotherapy.
While the suitability of cetuximab had been suggested in other trials, Prof Mehanna reports that it is not only non-superior to cisplatin for disease control and toxicity, but that patients receiving it actually fare worse, and it should no longer be offered.
For more on these results, watch their presentation at a press session.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.